P-glycoprotein in blood-brain barrier endothelial cells: Interaction and oligomerization with caveolins

Journal of Neurochemistry

Volumn 87, Issue 4, 2003, Pages 1010-1023

  Jodoin, Julie ^a   Demeule, Michel ^a   Fenart, Laurence ^b   Cecchelli, Roméo ^b   Farmer, Sarah ^c   Linton, Kenneth J ^c   Higgins, Christopher F ^c   Béliveau, Richard ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITÉ D'ARTOIS   (France)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Blood brain barrier; Brain; Caveolae; Caveolin; Endothelial cell; P glycoprotein

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; CHOLESTEROL; FILIPIN; GLYCOPROTEIN P; NYSTATIN;

ANIMAL CELL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CATTLE; CAVEOLA; CELL CULTURE; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; MOLECULAR WEIGHT; MUTATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

ANIMALS; ASTROCYTES; BINDING SITES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CATTLE; CAVEOLAE; CAVEOLIN 1; CAVEOLIN 2; CAVEOLINS; CELLS, CULTURED; COCULTURE TECHNIQUES; DOGS; ENDOTHELIUM, VASCULAR; KIDNEY; MACROMOLECULAR SUBSTANCES; MODELS, BIOLOGICAL; MUTAGENESIS, SITE-DIRECTED; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN TRANSPORT; RATS;

ANIMALIA; BOS TAURUS; BOVINAE;

EID: 0345255950     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02081.x     Document Type: Article

References (68)

1. Annabi B., Lachambre M., Bousquet-Gagnon N., Page M., Gingras D. and Béliveau R. (2001) Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem. J. 353, 547-553.
2. Arsenault A. L., Ling V. and Kartner N. (1988) Altered plasma membrane ultrastructure in multidrug-resistant cells. Biochim. Biophys. Acta. 938, 315-321.
3. Beaulieu É., Demeule M., Ghitescu L. and Béliveau R. (1997) P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326, 539-544.
4. Bendayan R., Lee G. and Bendayan M. (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Techn 57, 365-380.
5. Borst P., Evers R., Kool M. and Wijnholds J. J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst 92, 1295-1302.
6. Boscoboinik D., Debanne M. T., Stafford A. R., Jung C. Y., Gupta R. S. and Epand R. M. (1990) Dimerization of the P-glycoprotein in membranes. Biochim. Biophys. Acta 1027, 225-228.
7. Cecchelli R., Dehouck B., Descamps L., Fenart L., Buée-Scherrer V., Duhem C., Lundquist S., Rentfel M., Tropier G. and Dehouck M. P. (1999) In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 165-178.
8. Chu T. M., Lin T. H. and Kawinski E. (1994) Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem. Biophys. Res. Commun. 203, 506-512.
9. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R. and Melamed M. R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287.
10. Couet J., Li S., Okamoto T., Ikezu T. and Lisanti M. P. (1997b) Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272, 6525-6633.
11. Couet J., Sargiacomo M. and Lisanti M. P. (1997a) Interaction of a receptor tyrosine kinase, EGF-R., with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities, J. Biol. Chem. 272, 30429-30438.
12. Dallaire L., Tremblay L. and Béliveau R. (1991) Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem. J. 276, 745-752.
13. Decleves X., Régina A., Laplanche J. L., Roux F., Boval B., Launay J. M. and Scherrmann J. M. (2000) Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 60, 594-601.
14. Dehouck M. P., Jolliet-Riant P., Brée F., Fruchart J. C., Cecchelli R. and Tillement J. P. (1992) Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58, 1790-1797.
15. Demeule M., Wenger R. M. and Béliveau R. (1997) Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives. J. Biol. Chem. 272, 6647-6652.
16. Demeule M., Jodoin J., Gingras D. and Béliveau R. (2000) P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett. 466, 219-224.
17. Demeule M., Labelle M., Régina A., Berthelet F. and Béliveau R. (2001) Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 281, 827-834.
18. Demeule M., Poirier J., Jodoin J., Bertrand Y., Desrosiers R. R., Dagenais C., Nguyen T., Lanthier J., Gabathuler R., Kennard M., Jefferies W. A., Karkan D., Tsai S., Fenart L., Cecchelli R. and Béliveau R. (2002) High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83, 924-933.
19. Descamps L., Cecchelli R. and Torpier G. (1997) Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. J. Neuroimmunol. 74, 173-184.
20. Devault A. and Gros P. (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell Biol. 10, 1652-1663.
21. Dixon P. H., Weerasekera N., Linton K. J., Donaldson O., Chambers J., Egginton E., Weaver J., Nelson-Piercy C., de Swiet M., Warnes G., Elias E., Higgins C. F., Johnston D. G., McCarthy M. I. and Williamson C. (2000) Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet. 9, 1209-1217.
22. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R. and Betbeder D. (1999) Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 291, 1017-1022.
23. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M. and Pastan I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl Acad. Sci. USA 84, 265-269.
24. Golden P. L. and Pardridge W. M. (1999) P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res. 819, 143-146.
25. Ikezu T., Ueda H., Trapp B. D., Nishiyama K., Sha J. F., Volonté D., Galbiati F., Byrd A. L., Bassell G., Serizawa H., Lane W. S., Lisanti M. P. and Okamoto T. (1998) Affinity-purification and characterization of caveolins from the brain: differential expression of caveolin-1-2, and - 3 in brain endothelial and astroglial cell types. Brain Res. 804, 177-192.
26. Jetté L., Tetu B. and Béliveau R. (1993) High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta. 1150, 147-154.
27. Jetté L., Murphy G. F., Leclerc J. M. and Béliveau R. (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol. 50, 1701-1709.
28. Jetté L., Potier M. and Béliveau R. (1997) P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. Biochemistry 36, 13929-13937.
29. Lavie Y. and Liscovitch M. (2000) Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj. J. 17, 253-259.
30. Lavie Y., Fiucci G. and Liscovitch M. (1998) UP-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273, 32380-32383.
31. Lavie Y., Fiucci G., Czarny M. and Liscovitch M. (1999) Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells. Lipids 34, S57-S63.
32. Lavie Y., Fiucci G. and Liscovitch M. (2001) Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 49, 317-323.
33. Li S., Galbiati F., Volonté D., Sargiacomo M., Engelman J. A., Das K., Scherer P. E. and Lisanti M. P. (1998) Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranes. FEBS Lett. 434, 127-134.
34. Ling V., and Thompson L. H. (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83, 103-116.
35. Liscovitch M. and Lavie Y. (2000) Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci. 25, 530-534.
36. Luciani F., Molinari A., Lozupone E., Calcabrini A., Lugini L., Stringaro A., Puddu P., Arancia G., Cianfriglia M. and Fais S. (2002) P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 99, 641-648.
37. Luker G. D., Pica C. M., Kumar A. S., Covey D. F. and Piwnica-Worms D. (2000) Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 39, 7651-7661.
38. Michaely P. A., Mineo C., Ying Y. S. and Anderson R. G. (1999) Polarized distribution of endogenous Rac1 and RhoA at the cell surface. J. Biol. Chem. 274, 21430-21436.
39. Monier S., Parton R. G., Vogel F., Behlke J., Henske A. and Kurzchalia T. V. (1995) VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol. Biol. Cell. 6, 911-927.
40. Mora R., Bonilha V. L., Marmorstein A., Scherer P. E., Brown D., Lisanti M. P. and Rodriguez-Boulan E. (1999) Caveolin-2 localizes to the golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1. J. Biol. Chem. 274, 25708-25717.
41. Naito M. and Tsuruo T. (1992) Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells. Biochem. Biophys. Res. Commun. 185, 284-290.
42. Okamoto T., Schlegel A., Scherer P. E. and Lisanti M. P. (1998) Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J. Biol. Chem. 273, 5419-5422.
43. Parolini I., Sargiacomo M., Galbiati F., Rizzo G., Grignani F., Engelman J. A., Okamoto T., Ikezu T., Scherer P. E. and Mora R. (1999) Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J. Biol. Chem. 274, 25718-25725.
44. Poruchynsky M. S. and Ling V. (1994) Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells. Biochemistry 33, 4163-4174.
45. Razani B. and Lisanti M. P. (2001) Caveolins and caveolae: molecular and functional relationships. Exp. Cell Res. 271, 36-44.
46. Roninson I. B., Chin J. E., Choi K. G., Gros P., Housman D. E., Fojo A., Shen D. W., Gottesman M. M. and Pastan I. (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl Acad. Sci. USA 83, 4538-4542.
47. Rosenberg M. F., Velarde G., Ford R. C., Martin C., Berridge G., Kerr I. D., Callaghan R., Schmidlin A., Wooding C., Linton K. J. and Higgins C. F. (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J. 20, 5615-5625.
48. Rothnie A., Theron D., Soceneantu L., Martin C., Traikia M., Berridge G., Higgins C. F., Devaux P. F. and Callaghan R. (2001) The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur. Biophys. J. 30, 430-442.
49. Ruetz S. and Gros P. (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071-1081.
50. Sargiacomo M., Sudol M., Tang Z. and Lisanti M. P. (1993) Signal transducing molecules and glycosyl-phosphafidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J. Cell Biol. 122, 789-807.
51. Sargiacomo M., Scherer P. E., Tang Z., Kubler E., Song K. S., Sanders M. C. and Lisanti M. P. (1995) Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc. Natl Acad. Sci. USA 92, 9407-9411.
52. Schinkel A. H. (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194.
53. Schinkel A. H., Roelofs E. M. and Borst P. (1991) Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res. 51, 2628-2635.
54. Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P., Bems A. J. and Borst P. (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77, 491-502.
55. Schlegel A. and Lisanti M. P. (2000) A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J. Biol. Chem. 275, 21605-21617.
56. Schnitzer J. E., Oh P., Pinney E. and Allard J. (1994) Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 127, 1217-1232.
57. Shaul P. W. and Anderson R. G. W. (1998) Role of plasmalemmal caveolae in signal transduction. Am. J. Physiol. 275, L843-L851.
58. Simons K. and Toomre D. (2000) Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31-39.
59. Song K. S., Li S., Okamoto T., Quilliam L. A., Sargiacomo M. and Lisanti M. P. (1996) Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J. Biol. Chem. 271, 9690-9697.
60. Stewart P. A., Beliveau R. and Rogers K. A. (1996) Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J. Histochem. Cytochem. 44, 679-685.
61. Sugawara I., Hamada H., Tsuruo T. and Mori S. (1990) Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn J. Cancer Res. 81, 727-730.
62. Taylor J. C., Horvath A. R., Higgins C. F. and Begley G. S. (2001) The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interactions. J. Biol. Chem. 276, 36075-36078.
63. Ueda K., Yoshida A. and Amachi T. (1999) Recent progress in P-glycoprotein research. Anticancer Drug Des. 14, 115-121.
64. Virgintino D., Robertson D., Errede M., Benagiano V., Girolamo F., Maiorano E., Roncali L. and Bertossi M. (2002a) Expression of P-glycoprotein in human cerebral cortex microvessels. J. Histochem. Cytochem. 50, 1671-1676.
65. Virgintino D., Robertson D., Errede M., Benagiano V., Tauer U., Roncali L. and Bertossi M. (2002b) Expression of caveolin-1 in human brain microvessels. Neuroscience 115, 145-152.
66. Yamamoto M., Toya Y., Schwencke C., Lisanti M. P., Myers M. G. and Ishikawa Y. (1998) Caveolin is an activator of insulin receptor signaling. J. Biol. Chem. 273, 26962-26968.
67. Yang C. P. H., Galbiati F., Volonté, D., Horwitz S. B. and Lisanti M. P. (1998) Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 439, 368-372.
68. Zhang Y., Han H., Elmquist W. F. and Miller D. W. (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876, 148-153.